Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Agios Pharmaceuticals and Novartis Pharmaceuticals Corporation.

Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta Online

Release Date: December 21, 2017
Expiration Date: December 21, 2018
Media: Internet - based


Activity Overview

Physicians’ Education Resource®, LLC (PER) is pleased to present an archived CME activity of the continuing medical education (CME)-certified activity titled “Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta.”   This program is an archived version of the live-streamed interactive webcast held on December 14, 2017 and led by world renowned Acute Myeloid Leukemia (AML) experts: Richard Stone, MD; Naval Daver, MD; and Etyan Stone, MD.

The Rapid Reviews in Oncology® format presents an archive of a live-stream, interactive broadcast from a professional studio to rapidly update physicians on data that was recently presented at the American Society of Hematology (ASH) Annual Meeting in December 2017. The program consists of an in-studio panel discussion between AML experts highlighting implications and applications of ground-breaking data in the treatment and management of AML presented at the 2017 ASH Annual Meeting. 

The Rapid Reviews in Oncology® program on AML from ASH brings conference-caliber education to the convenience of your screen!

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Agios Pharmaceuticals and Novartis Pharmaceuticals Corporation.

CME Activity Table of Contents

  • Introductions and Opening Remarks on AML
  • Advances in FLT3-Targeted Agents in Patients With AML
  • New Developments in IDH Inhibition in AML
  • Expanding the Array of Therapeutic Targets in AML

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This activity is directed toward medical oncologists, oncologist/hematologists and hematologists who treat patients with acute myeloid leukemia. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of leukemia patients are also invited to participate. 

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Explain current treatment pathways for the management of patients with AML
  • Assess recent clinical trial findings that have evaluated novel approaches for patients with AML
  • Place new evidence concerning emerging strategies for the management of AML in the context of evolving treatment paradigms in the field

Faculty, Staff, and Planners' Disclosures


Richard Stone, MD
Professor of Medicine, Harvard Medical School
Chief of Staff
Director, Adult Leukemia
Dana-Farber Cancer Institute
Boston, MA

Disclosure: Consultant: Abbvie, Agios, Amgen, Argenix, Arog, Astellas, Celator, Celgene, Cornerstone, Fujifilm, Janssen, Jazz, Juno, Karyopharm, Merck, Novartis, Ono, Orsenix, Otsuka, Pfizer, Roche, Seattle Genetics, Sumitomo, Sunesis, Xenetic. Board Member and Advisory Committee: Actinium. Research Funding: Agios, Novartis.


Naval G. Daver, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure: Grant/Resaerch Support: BMS, Pfizer, Daichi, Sunesis, Incyte, Servier, Immunogen, Karyopharm. Consultant: Novartis, Otsuka, Pfizer, BMS, Celgene, Agios, Jazz, Incyte, Servier, Immunogen

Eytan M. Stein, MD
Assistant Attending Physician
Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Grant/Research Support: Novartis, Agios, Celgene

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By